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The need for rapid methods to accurately detect methicillin-resistant Staphylococcus aureus (MRSA) is widely
acknowledged, and a number of molecular assays are commercially available. This study evaluated the Xpert
MRSA assay, which is run on the GeneXpert real-time PCR platform (Cepheid) for use in a clinical laboratory.
The following parameters were investigated: (i) the limits of detection (LoDs) for four MRSA strains; (ii) the
ability to detect isolates of MRSA from a collection representative of MRSA in Ireland since 1974 (n  114)
and the ability to detect control strains with staphylococcal cassette chromosome mec types IVa (IV.1.1.1), IVb
(IV.2.1.1), IVc (IV.3.1.1), IVd (IV.4.1.1), V (V.1.1.1), VT, and VI; and (iii) performance in a clinical trial with
swabs from nose, throat, and groin/perineum sites from 204 patients, where results were compared with those
obtained by direct and enrichment cultures. The average LoD of the four test strains was 610 CFU/ml
(equivalent to 58 CFU/swab). All 114 MRSA isolates and 7 control strains tested were detected. Sensitivity,
specificity, and positive and negative predictive values for clinical specimens from all sites investigated were
90%, 97%, 86%, and 98%, respectively, but throat specimens yielded poor sensitivity (75%). Sensitivity,
specificity, and positive and negative predictive values for nasal specimens were 95%, 98%, 90%, and 99%,
respectively. Overall, the assay was rapid and easy to perform, but performance might be enhanced by the
inclusion of an equivocal interpretive category based on analysis of all available amplification data.
The rapid detection of methicillin-resistant Staphylococcus
aureus (MRSA) along with an early implementation of appro-
priate intervention has been reported to reduce the prevalence
of MRSA, especially in critical care areas (1, 5, 8). In 2004,
Huletsky et al. described a novel real-time PCR assay targeting
DNA sequences in the region of the open reading frame orfX,
where the staphylococcal cassette chromosome mec (SCCmec)
integrates into the S. aureus chromosome (7). SCCmec carries
the resistance determinant mecA, which encodes methicillin
resistance and exhibits at least six different structural types and
numerous subtypes (SCCmec; T. Ito, Department of Bacteri-
ology, School of Medicine, Juntendo University, Japan. http:
//www.staphylococcus.net/ [10 November 2007, accession
date]). To detect MRSA with all SCCmec types known in 2004,
the assay used five forward primers designed to target se-
quences within SCCmec, while a sixth reverse primer and three
probes were specific for orfX (7). Unlike earlier amplification
techniques investigating mecA, nuc, and/or fem genes, this as-
say could distinguish between MRSA and mixtures of methi-
cillin-susceptible S. aureus (MSSA) and methicillin-resistant
coagulase-negative staphylococci (MR-CNS) (3, 7). The assay
became commercially available as the IDI-MRSA assay and is
currently marketed as the BD GeneOhm MRSA assay.
In 2007, a new real-time PCR MRSA assay also targeting
DNA sequences in the chromosomal orfX-SCCmec junction
became available. This assay is the Xpert MRSA kit (Cepheid,
Sunnyvale, CA), and it is used in conjunction with the
GeneXpert real-time PCR platform (Cepheid). In the Xpert
MRSA assay, DNA from specimens is extracted, amplified,
and detected in separate chambers of single-use disposable
cartridges which contain freeze-dried beads with all reagents
required for the real-time process. Sample preparation time is
minimal and the PCR time is 75 min. The assay is validated for
use with nasal specimens taken on Copan swabs with Stuart’s
liquid transport medium from patients at risk for colonization
with MRSA and has a quoted limit of detection (LoD) of 80
CFU per swab (Xpert MRSA assay product insert; Cepheid,
Sunnyvale, CA).
The present study evaluated the Xpert MRSA assay for use
in a clinical laboratory. The following parameters were inves-
tigated: (i) LoD, (ii) ability to detect isolates of MRSA in a
collection representative of MRSA in Ireland since 1974 and to
detect isolates carrying recently described SCCmec elements,
and (iii) performance in a clinical trial with swabs from nose,
throat, and groin/perineum sites from 204 patients.
MATERIALS AND METHODS
LoD assays. LoD assays of the Xpert MRSA kit were performed using four
MRSA isolates. These isolates exhibited a range of oxacillin MICs and were
representative of strains recovered in Ireland, as described previously (16). LoDs
were determined for 10-fold dilutions of suspensions of each strain (from 105 to
* Corresponding author. Mailing address: National MRSA Reference
Laboratory, St. James’s Hospital, James’s St., Dublin 8, Ireland. Phone:
353 1 410 3662. Fax: 353 1 410 3666. E-mail: arossney@stjames.ie.
 Published ahead of print on 6 August 2008.
3285
 o
n
 M
arch 12, 2016 by IRIS
http://jcm.asm.org/
D
ow
nloaded from
 
101 CFU/ml) adsorbed onto Copan Stuart’s liquid transport medium double
swabs (Copan 139C swabs; Copan Italia SPA, Brescia, Italy). Colony counts
(CFU/ml) of each dilution were determined by spiral plating onto brain heart
infusion agar (Oxoid CM375; Oxoid Ltd., Basingstoke, United Kingdom) by use
of a Whitley automatic spiral plater (WASP; Don Whitley Scientific Ltd., Ship-
ley, England). LoDs were determined for all four isolates in pure culture and in
the presence of a mixed cocktail of bacteria consisting of 10 MSSA isolates
(which were mecA negative by in-house conventional PCR), five MR-CNS iso-
lates, and single isolates of Moraxella catarrhalis, Escherichia coli, and Candida
species (16). Each component of the cocktail was tested with the Xpert MRSA
kit prior to use. The bacterial suspensions were also adsorbed onto Transwabs
with Amies’ clear transport medium (MW170 Transwabs; Medical Wire and
Equipment Company, Corsham, England) for subsequent culture.
One Copan swab from each dilution was investigated for the presence of
MRSA by use of the Xpert MRSA kit on a GeneXpert DX system, version 1.2
(Cepheid, Sunnyvale, CA), according to the manufacturer’s instructions. The
second Copan swab was reserved for repeat testing if required.
The corresponding Transwab was cultured onto Columbia agar (LabM Lab1;
International Diagnostics Group plc, Bury, United Kingdom) containing 7%
(wt/vol) horse blood (BA), onto MRSA-Select chromogenic agar (CA) (Bio-Rad
63747; Bio-Rad Life Science Group, Marnes-La-Coquette, France), and into 4
ml tryptic soy broth (BD 211825; Becton Dickinson) containing 6.5% NaCl (salt
TSB). After 18 h of incubation at 35°C, enrichment broths (10-l volumes) were
subcultured onto BA and CA. All isolates from enriched and direct culture were
identified as S. aureus and confirmed as MRSA as described previously (16).
To express the LoD value as CFU/swab, the volume adsorbed by either Copan
swabs or Transwabs was determined by measuring the difference in weights of
bijoux of saline before and after adsorbance for 10 s by each of 10 Copan swabs
and 10 Transwabs. The average of the 10 replicate readings was taken as the
average volume adsorbed by each swab type.
LoDs were recorded as the lowest concentration to give positive results by the
Xpert MRSA kit or by culture. The Xpert MRSA assay defines a specimen as
MRSA positive if the MRSA target has a cycle threshold (CT) value within the
valid range (36 cycles). The LoDs for both culture methods were calculated on
the basis of growth of 1 colony on a single culture medium or 1 colony on
more than one medium and were expressed as averages of the counts obtained
with the four isolates.
MRSA isolates and MRSA control strains. To ensure that the kit could detect
MRSA strains prevalent in Ireland, 114 MRSA isolates representative of MRSA
recovered in Ireland were investigated (isolate details are shown in Table 1) (18).
In addition, seven control MRSA strains representing isolates carrying SCCmec
IV subtypes IVa (IV.1.1.1), IVb (IV.2.1.1), IVc (IV.3.1.1), IVd (IV.4.1.1),
SCCmec V (V.1.1.1), VT, and VI were tested (2, 4, 13). Isolates were prepared
in saline suspensions at concentrations of102 CFU/ml above the LoD of the kit
(determined in the present study) and adsorbed onto Copan swabs and Tran-
swabs. One swab of each pair of Copan swabs was tested with the Xpert MRSA
assay, and the Transwab was cultured onto BA and CA. Any isolate that was
negative by use of the kit was retested in pure culture and at one 10-fold-higher
concentration.
Clinical trial. The clinical trial was undertaken with specimens from patients
attending St. James’s Hospital (SJH), a large 936-bed tertiary-referral hospital
catering to all specialties except maternity and pediatric services. A difficulty
encountered when designing the clinical trial was that specimens processed by
the Xpert MRSA assay could not be used for subsequent culture because the
kit’s elution reagent contains sodium hydroxide and quanidium thiocyanate.
Ethical approval was obtained to take duplicate specimens from nose, throat, and
groin/perineum sites from patients undergoing routine MRSA screening with
Copan swabs after specimens on Transwabs had been obtained for routine
diagnostic culture. Criteria for routine screening were as described previously
(16).
Specimens collected with Copan swabs were tested using the Xpert MRSA kit
according to the manufacturer’s instructions as soon as possible after collection.
Specimens were tested in batches of eight by use of two four-module GeneXpert
machines. If not tested immediately, specimens were stored at 4°C. Following
processing, all specimens were stored at 4°C until all molecular and culture
testing was complete. Specimens yielding invalid results were retested using the
second Copan swab.
Specimens collected with Transwabs were inoculated onto CA in the diagnos-
tic laboratory and subsequently cultured into salt TSB. After incubation at 35°C
for 18 h, 10-l volumes of salt TSB were subcultured onto BA and CA. Growth
was identified as MRSA as described previously, and the presence of mecA was
confirmed by a conventional in-house end-point PCR assay (16). All MRSA
isolates were stored at 70°C on cryoprotective beads (Protect beads; Technical
Service Consultants Limited, Heywood, United Kingdom). Bacterial growth
from BA plates from specimens yielding positive Xpert MRSA kit results and
negative MRSA culture results were also preserved at 70°C on cryoprotective
beads. Discrepancies between culture and kit results were investigated by salt
enrichment culture of the second Copan swab (if available).
MRSA isolates recovered from specimens yielding kit-negative results were
prepared in suspensions in saline at concentrations of 105 CFU/ml, adsorbed
onto Copan swabs, and tested using the Xpert MRSA kit. Bacterial growth from
BA plates from specimens which tested Xpert MRSA kit positive but from which
MRSA was not recovered in culture was similarly tested to exclude the possibility
that such positive results occurred as a result of MSSA or MR-CNS.
Control strains. S. aureus ATCC 25923 and S. aureus ATCC 43300 were used
as negative and positive controls, respectively. S. epidermidis ATCC 12228 was
also used as a negative control as recommended by the manufacturer. Control
isolates were prepared in saline suspensions containing 105 CFU/ml and ad-
sorbed onto Copan swabs prior to testing. For determining LoDs, positive and
negative controls were included with each batch of tests. When MRSA strains
were tested, a negative control was included each day. During the clinical trial,
a positive control was included once a week and after any batch of specimens
where all specimens yielded kit-negative results. S. aureus ATCC 25923 and S.
aureus ATCC 43300 were also included as negative and positive controls with
each batch of CA plates.
Statistics. In the clinical trial, the sensitivities, specificities, and positive and
negative predictive values of the Xpert MRSA kit were calculated for all spec-
imen types by comparison with direct culture and by comparison with enrichment
culture. Because the Xpert MRSA kit detects DNA which may come from
nonviable MRSA, whereas culture detects viable organisms only, Xpert MRSA
kit-positive specimens that were culture negative were considered as giving
possible true-positive results if the patient had been previously positive for
MRSA within the last 2 years or was positive at another site. Sensitivities,
specificities, and positive and negative predictive values were also calculated
using these amended results for all specimen sites and for each specimen site
individually. Further calculations were made when patients were grouped into
those who were known to have been previously positive for MRSA and those
who were not known to have been previously positive.
TABLE 1. MRSA isolates (n  114) used to determine whether
the Xpert MRSA kit could detect all strains of MRSA
prevalent in Ireland
MLST
(no. of isolates)
SCCmec
typeb AR type (no. of isolates)
c
ST5d (10) II 07.3d (3); 07.4 (5); 11 (2)
ST5 (1) IV Unfamiliare (1)
ST8f (11) IV or IVv 43 (8); Unfamiliare (3f)
ST8 (26) II or IIv 13 (7); 14 (15); New03 (3);
05 (1)
ST12 (1) IV NT (1)
ST22 (14) IV 06 (13); NT (1)
ST30 (2) IV NT (2)
ST34 (1) IV NT (1)
ST36 (3) II 07.0 (2); 07.2 (1)
ST45 (1) IV NT (1)
ST239 (13) III or IIIv 01 (4); 09 (3); 15 (2); 44 (3);
23 (1)
ST247 (3) IA 22 (2); New02 (1)
ST250 (4) I or Iv 02 (4)
—a (6) — 07 (2); New02 (1); 06 (1);
SCV (2)
— (18) — PVL-positive community-
acquired MRSA (18)
a —, not done.
b “v” suffixes indicate previously reported variants of SCCmec types (14, 18).
c Antibiogram-resistogram (AR) types were determined from the patterns of
resistance obtained when isolates were tested by disk diffusion against a panel of
23 antimicrobials as described previously (17). NT indicates AR patterns that
were designated “no type” pending the results of DNA macrorestriction diges-
tion analysis; PVL, Panton-Valentine leucocidin; SCV, small-colony variant.
d One isolate was a double-locus variant of ST5.
e Unfamiliar AR pattern.
f Two isolates were single-locus variants of ST8.
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RESULTS
LoD assays. The average LoD value for the four MRSA test
isolates in pure culture with the Xpert MRSA kit using Copan
swabs was 610 CFU/ml. The average volume adsorbed by Co-
pan swabs was 95 l/swab; hence, the average LoD/swab was
58 CFU. The amplification data obtained with two of these
isolates suggested that both isolates were positive at concen-
trations below 58 CFU/swab, but since CT values of 36.4 and
37.1 were obtained, the kit recorded negative results (Fig. 1A
and B). The average LoD values of direct and enrichment
cultures using Transwabs were 750 CFU/ml and 40 CFU/ml,
respectively. The average volume adsorbed by Transwabs was
228 l/swab; hence, the average LoDs of direct and enrichment
cultures were 171 and 9 CFU/swab, respectively. The average
LoD of the kit for the four test isolates in the presence of
mixed flora was the same as the LoD obtained in pure culture
(600 CFU/ml; 57 CFU/swab).
During the preparation of the mixed-culture cocktail, the
MSSA component yielded a kit-positive result. When the cock-
tail was prepared using fresh subcultures of the same 10 MSSA
isolates, the cocktail tested negative and continued to test kit
negative on the successive days when the LoDs of the kit were
determined. However, when the cocktail was retested follow-
ing completion of the LoD assays, the kit again recorded a
positive result, although the accompanying amplification curve
failed to demonstrate evidence of efficient amplification, sug-
gesting that this could be a false-positive result. Conversely,
although the Xpert assay always recorded negative results for
FIG. 1. Amplification data obtained with the Xpert MRSA kit for two of the four MRSA isolates used in LoD assays (A and B), two replicates
of S. aureus ATCC 25923 (C and D), and two replicates of an MRSA isolate (tested at 106 CFU/ml) recovered from a specimen yielding a
kit-negative result (E and F). All isolates demonstrated kit-negative results with appropriate amplification of the internal control. The amplification
plots in panels A and B demonstrate an exponential rise in fluorescence emission that is consistent with amplification of the MRSA target,
suggesting false-negative kit results. The amplification data shown in panel C are representative of results obtained with most replicates of S. aureus
ATCC 25923, but on some occasions this MSSA isolate yielded a plot suggestive of MRSA target amplification (panel D). The data shown in panels
E and F were obtained from an MRSA isolate tested at a bacterial concentration of 106 CFU/ml on two separate occasions. While both replicates
yielded kit-negative results, one replicate demonstrated evidence of MRSA target amplification (panel F).
VOL. 46, 2008 Xpert MRSA ASSAY FOR RAPID DETECTION OF MRSA 3287
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the MSSA control strain S. aureus ATCC 25923 (Fig. 1C), on
some occasions the amplification data demonstrated evidence
of amplification of MRSA target DNA with CT values just
exceeding the cutoff value of 36 cycles (for example, a CT value
of 37.3) and accompanying amplification curves showed an
exponential rise in fluorescence emission (Fig. 1D).
MRSA isolates and MRSA control strains. When this study
was designed, it was intended that the MRSA isolates and
MRSA control strains would be tested in the presence of the
mixed cocktail of bacteria to mimic normal flora, but the in-
consistent results with the MSSA component of the cocktail
suggested that this would be unwise. Isolate suspensions were
therefore prepared in a pure culture in saline at a concentra-
tion of 104 CFU/ml (i.e., 102 CFU/ml above the LoD de-
termined in the present study). All MRSA isolates except two
yielded positive Xpert MRSA kit results; one negative isolate
was positive upon repeat testing, and the second negative iso-
late was positive when retested at a higher concentration (105
CFU/ml). All seven control MRSA strains yielded positive
results.
Clinical trial. Six hundred twelve specimens from 204 pa-
tients were investigated. An overview of the numbers of posi-
tive specimens obtained with the Xpert MRSA kit, with direct
culture, with enrichment culture, and with amended results is
shown in Table 2. By use of amended results, Xpert MRSA
kit-positive specimens that were culture negative were consid-
ered to be true-positive results if the patient had been previ-
ously positive for MRSA or was positive at another site. MRSA
was detected in 99 specimens (16.2%; 99/612) from 58 patients
(28.4%; 58/204) by the Xpert MRSA kit. Direct culture yielded
positive results from 59 specimens (9.7%; 59/606) from 37
patients (18.3%; 37/202); direct culture results were unavail-
able for 6 specimens from 2 patients. Specimens from 89 spec-
imens (14.5%; 89/612) from 45 patients (22.1%; 45/204) were
positive by enrichment culture. No specimen was culture pos-
itive by direct culture and negative by salt enrichment culture.
When amended results were calculated, 95 specimens (15.5%;
95/612) from 47 patients (23.0%; 47/204) were deemed posi-
tive. Sixteen specimens from 14 patients yielded invalid Xpert
MRSA kit results upon initial testing, but upon repeat testing
only four specimen results remained invalid (throat [n  3];
groin [n  1]).
MRSA isolates from all but 2 of the 19 culture-positive
kit-negative specimens were kit positive when tested in pure
culture at a concentration of 105 CFU/ml. One of the two
negative isolates tested positive when retested at 105 CFU/ml;
the other remained kit negative when retested at both 105 and
106 CFU/ml (Fig. 1E). Repeat testing of the latter isolate at 106
CFU/ml also yielded a negative kit result, but evidence of
amplification (with a CT value of 36.7) was noted on this
occasion (Fig. 1F). This isolate was mecA gene positive by
conventional in-house endpoint PCR.
Non-MRSA bacterial growths from BA plates from speci-
mens which were kit positive and MRSA culture negative were
also tested by the kit, but growths from all of these non-MRSA
cultures yielded negative results with the kit.
Statistics. The sensitivity, specificity, and positive and neg-
ative predictive values of the Xpert MRSA kit compared with
those obtained using direct culture, enrichment culture, and
amended results are shown in Table 3. With nasal swabs, when
the amended results were considered, the sensitivity of the kit
was 95%. In comparison, its sensitivity for specimens from the
throat was only 75%. When the Xpert MRSA kit results from
specimens from all sites were compared with amended results,
the overall sensitivity, specificity, and positive and negative
predictive values were 90%, 97%, 86%, and 98%, respectively
(Table 3). When this analysis was restricted to specimens from
patients who were previously recorded as being MRSA posi-
tive, the sensitivity of the kit for nasal specimens was 93%,
whereas with specimens from patients with no record of being
previously positive (i.e., new MRSA patients), the sensitivity
for nasal specimens was 100%.
DISCUSSION
Ireland has a serious problem with MRSA, and the propor-
tion of MRSA among S. aureus blood culture isolates is among
the highest in Europe (11). It has been reported that in areas
where MRSA is endemic, the introduction of a full “search-
and-destroy” approach, including screening of all patient con-
tacts of all index cases and the institution of precautionary
isolation for all such contacts, could reduce the prevalence of
MRSA to 1% within 6 years (1). It has also been reported
that rapid detection of carriage has an important role to play in
such a “search-and-destroy” strategy (1). A study investigating
the value of rapid diagnostic tests (RDTs) for MRSA when
used for admission screening to a critical care area reported a
reduction in the incidence of transmission of MRSA from
13.89/1,000 patient days to 4/1,000 patient days (5).
While RDTs may play a major role in reducing the preva-
lence of MRSA, the chosen method must be sensitive and
specific and have good positive and negative predictive values.
Failure to recognize a particular strain of MRSA can have very
serious consequences, as was recently experienced in The
Netherlands, where phenotypic tests failed to detect a mecA-
positive strain with a low oxacillin MIC in one hospital. Over a
TABLE 2. Overview of results obtained with the Xpert MRSA kit
and culture from 612 specimens
Reference method
and result
No. of specimens with Xpert MRSA kit result of:
Positive Negative Invalidb Total
Direct culturea
Positive 52 7 59
Negative 46 497 4 547
Total 98 504 4b 606a
Enrichment culture
Positive 70 19 89
Negative 29 490 4 523
Total 99 509 4b 612
Amended resultsc
Positive 85 10 95
Negative 14 499 4 517
Total 99 509 4b 612c
a Direct culture results were unavailable for six specimens from two patients.
b Four isolates were invalid by the Xpert MRSA kit.
c Amended results include numbers of specimens that were culture positive
and those that were Xpert MRSA kit positive but culture negative from previ-
ously positive patients or from patients from whom a specimen from another site
was positive.
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2-year period, this strain spread extensively not only within that
hospital but in other hospitals also and it took over a year to
control the resulting outbreaks (8).
As more molecular RDTs for MRSA become available, the
choice of an appropriate assay becomes more difficult. Evalu-
ating new molecular assays is expensive and time-consuming,
and it is hard to exclude confounding variables, even when
assays are evaluated at the same time. For example, the
present study required duplicate specimens to allow compari-
son between the Xpert MRSA kit and enrichment culture.
Because sampling using the routine Transwab method had to
be undertaken prior to sampling with Copan swabs to ensure
that the routine diagnostic culture protocol was not compro-
mised by the clinical trial, it is possible that less material was
available on the Copan swabs for detection by the Xpert
MRSA assay. In contrast, in an earlier study evaluating the
IDI-MRSA kit on the SmartCycler platform, swabs were cul-
tured by salt enrichment after they had been used with the kit
(16). In that evaluation, however, the LoD of salt enrichment
culture (by use of Transwabs) was 240 CFU/ml (55 CFU/swab),
whereas the LoD of salt enrichment culture (by use of Tran-
swabs) in the present study was 9 CFU/swab, indicating that
the Xpert MRSA kit was subjected to a more rigorous evalu-
ation. A possible explanation for the lower LoD of salt enrich-
ment culture in the present study is that the volume of medium
used for salt enrichment was 4 ml, whereas the protocol in the
IDI-MRSA kit evaluation used 1-ml volumes and enrichment
culture was performed after material on the swab was removed
for testing with the IDI-MRSA kit. Interestingly, the inclusion
of enrichment culture increased the number of culture-positive
specimens by 23% in the earlier study and by 51% (30/59) in
the present study (16).
The Xpert MRSA assay demonstrated an average LoD (58
CFU/swab) threefold lower than that for direct culture (171
CFU/swab) but sixfold higher than that for enrichment culture
(9 CFU/swab). In comparison, the earlier IDI-MRSA kit eval-
uation reported an average LoD value of 2,000 CFU/ml
(equivalent to 190 CFU/swab), which was similar to the LoD of
direct culture but 10-fold higher than the LoD of enrichment
culture (16). The LoDs of direct culture with Transwabs were
comparable in both studies: 171 CFU/swab in the present study
and 800 CFU/ml (182 CFU/swab) in the earlier study (16).
The Xpert MRSA assay detected all MRSA isolates investi-
gated, including control isolates exhibiting SCCmec V, VT, and
VI (2, 4, 13). Although not investigated here, both Xpert MRSA
assay and IDI-MRSA are reported to lack sensitivity when de-
tecting the pulsed-field gel electrophoresis-nontypeable MRSA
strain associated with pigs in The Netherlands (15, 19).
In the clinical trial, the Xpert MRSA assay exhibited sensi-
tivities of 95% and 97% for detecting MRSA from nasal and
groin/perineum sites but had difficulty detecting MRSA DNA
from throat specimens (sensitivity, 75%). Interestingly al-
though the previous evaluation of the IDI-MRSA kit reported
lower sensitivities for nose and groin/perineum specimens
(90% and 88%, respectively), specimens from the throat
yielded a higher sensitivity (89%) (16).
A major difficulty evaluating molecular assays for the detec-
tion of MRSA from clinical specimens is defining true-positive
and -negative specimens. In the present study, data were ana-
lyzed by direct comparison with culture, but to overcome the
problem of considering all kit-positive culture-negative speci-
mens as false-positive kit results, kit performance was analyzed
using amended results where kit-positive culture-negative re-
sults from patients who were previously positive for MRSA
were regarded as true-positive results. By use of these
amended results for comparison, the sensitivities and specific-
ities of direct culture, enrichment culture, and the Xpert
MRSA assay were 60.6% and 99.6%, 84.2% and 98.3%, 89.5%
and 97.3%, respectively. However, this comparison is not com-
pletely valid and may overestimate the sensitivity of the assay
and underestimate that of culture because culture-negative
results from patients who have undergone successful treatment
for MRSA should not be considered false-negative culture
results.
Despite the encouraging findings of the present study, the
overall performance of the Xpert MRSA assay might be im-
proved if result interpretation took account of all available
assay data. The manufacturer’s interpretation is based on the
application of a CT cutoff value of 36 cycles, with specimens
being recorded as MRSA positive if the CT is 36 and MRSA
negative if the CT is36, regardless of the presence or absence
of evidence of amplification (the former being demonstrated
by an amplification curve indicating an exponential rise in
fluorescence emission). Data obtained in the present study
suggested that this CT cutoff value might have introduced false-
negative results both in the LoD investigations and during the
TABLE 3. Sensitivity, specificity, and positive and negative predictive
values of the Xpert MRSA kit compared with those from direct
and enrichment cultures from nose, throat, and
groin/perineum specimens
Reference method
and analysis group Site
d
Value (%) of Xpert MRSA kit
Sensitivity Specificity PPVe NPVf
Direct culture All 88 92 53 99
Enrichment culture All 79 94 71 96
Nose 84 92 67 97
Throat 63 98 83 93
Groin/perineum 92 94 69 99
Amended resultsa
All patients All 90 97 86 98
Nose 95 98 90 99
Throat 75 98 88 96
Groin/perineum 97 96 80 99
Previously positive All 87 100 100 87
patientsb Nose 93 100 100 88
Throat 73 100 100 77
Groin/perineum 95 100 100 96
Patients who were All 96 97 62 100
not previously Nose 100 97 67 100
positivec Throat 83 98 63 99
Groin/perineum 100 95 59 100
a For further explanation of amended results, see Table 2, footnote c.
b Analysis restricted to specimens from patients who were previously MRSA
positive. With these specimens, kit-positive culture-negative specimens were also
included as true positives because the patients were known to have been previ-
ously positive for MRSA.
c Analysis restricted to specimens from patients with no record of being pre-
viously MRSA positive. With these specimens, kit-positive culture-negative spec-
imens were also included as true positives if the patient was positive for MRSA
at another site.
d All, nose, throat, and groin/perineum.
e PPV, positive predictive value.
f NPV, negative predictive value.
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clinical trial, where some tests (n  14) demonstrated clear
evidence of MRSA amplification but CT values exceeded 36
cycles (Fig. 1A, B, and F). Conversely, false-positive results
may have also occurred (with the MSSA component of the
mixed-culture cocktail, e.g.) where CT values of 36 were
obtained and reported as positive but amplification curves
failed to demonstrate an exponential rise. The inclusion of an
equivocal interpretative category for tests where the amplifi-
cation data of the MRSA target DNA fail to support the CT
cutoff result warrants investigation.
Aside from the interpretative difficulties associated with the
use of the CT cutoff value, findings from the present study also
indicate that false-positive results may have occurred, due per-
haps to a lack of specificity of the assay’s proprietary target
sequence for MRSA at the SCCmec-orfX junction. There are
increasing numbers of reports of SCC elements that do not
contain mecA, for example, SCCcap1 in MSSA, which inte-
grates into the SCCmec chromosomal attachment site attB at
the end of orfX (9, 10, 12). Although the Xpert assay recorded
negative results for the MSSA control, S. aureus ATCC 25923,
on some occasions the accompanying amplification curves
demonstrated evidence of amplification of target DNA (Fig.
1D), suggesting that like the IDI-MRSA assay, the Xpert
MRSA kit may have the problem of detecting SCC in MSSA
strains such as S. aureus ATCC 25923, which may be why the
manufacturer recommends the use of S. epidermidis ATCC
12228 as the negative control (6). This problem requires fur-
ther investigation.
While the Xpert MRSA assay requires more interpretation
than currently suggested by the manufacturer, it was found to
perform well with nasal and groin/perineum specimens. It is
rapid and easy to use and has the advantage of random access
(i.e., an urgent specimen can be accommodated because spec-
imens do not need to be tested in batches). Relative to culture,
it is expensive, and results need to be confirmed by culture. A
more extensive prospective study is warranted to determine its
role in clinical practice in Ireland. A question that such a
prospective clinical study might investigate is the duration of
kit-positive results from specimens from patients who have
been successfully treated for MRSA and whether there is a
period during which previously culture-positive patients should
not be screened by molecular methods. These data could in-
form how kit-positive results from patients who are known to
have been previously positive for MRSA should be interpreted.
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